TickerTalks
Browse all tickers →
TickerTalks›$LLY
LLLLY

Eli Lilly and Company

Strong FundamentalsStrong FundamentalsRevenue growing 56% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (1.2K/wk), no spike
$LLY·$1.1T·Drug Manufacturers - General·Healthcare
$1186.10+0.1%YTD+10.2%1Y+63.2%
Price updated 5m ago·X counts updated 2d ago
LLLLY
$LLYEli Lilly and Company
$1,186.10+0.11%1.2k posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $LLY on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

1,233X posts · last 7 days
Sep 11Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $LLY's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 59% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data20 posts analyzed · as of 2026-09-28

Eli Lilly bulls point to Foundayo capturing 30%+ of new oral GLP-1 patients, Lilly products accounting for 70% of new Medicare GLP-1 starters, a $6.5B Houston manufacturing groundbreaking, and two fresh FDA approvals including once-weekly insulin. The tirzepatide concentration risk (~70% of sales next year) is the one measured concern.

Read what X is saying about $LLY

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $LLY — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-28

The move is getting stronger, with heavier trading behind it.

Eli Lilly is the GLP-1 leader, just landed two fresh FDA approvals, and is inking a Kroger/Instacart delivery deal — the compounding chip earns itself again.

Eli Lilly runs the GLP-1 franchise that has redefined diabetes and obesity treatment (Mounjaro, Zepbound) — plus a broad pipeline in immunology, oncology, and CNS. The stock has quietly reaccelerated with fresh approvals landing and near-52-week highs.

  • The revenue print is stunning for a mega-cap: Q1 revenue grew 55% YoY to $19.8B at 46% operating margins and a 101% return on equity — this is a $1T pharma growing like a mid-cap.
  • The FDA news flow this week is a real tailwind: Onswik (a once-weekly basal insulin for T2D) and Olumiant (baricitinib) for pediatric alopecia both cleared FDA — additive to the top line, and both real launches.
  • The Kroger/Instacart same-order GLP-1 delivery arrangement is a distribution win: it lowers friction for Zepbound refills and pulls Lilly deeper into the retail-pharmacy stack — small on day one, meaningful compounding.

Q3 earnings on Oct 29 is where the top-line has to keep printing — a beat and a raise seals the compounding chip; a miss on GLP-1 volumes and the multiple gets pressured because the market has fully priced acceleration.

Agrees with X sentimentX bulls anchor on BMO's $1,400 PT, incretin expansion, and Zepbound/Mounjaro patents into the mid-2030s — every piece is backed by the Q1 print (+55% revenue) and the fresh FDA news. Clean agreement, with no meaningful counter in the tape.

What to watch: Q3 earnings on Oct 29 — a beat plus a raise seals the compounding chip; a miss on GLP-1 volumes and the multiple gets pressured because the market has fully priced acceleration.

On the calendar: 2026-10-29 — Q3 earnings

fresh fda approvalsglp1 franchisedistribution win

Read the AI verdict on $LLY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity, plus Kisunla for Alzheimer's, with massive manufacturing expansion.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $LLY.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $LLY

Neutral — Makes GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity, plus Kisunla for Alzheimer's, with massive manufacturing expansion.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+20.3%YTD
+46.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
40.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
32.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
45.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
14.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
101%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
83.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$8.38$6.40+30.9%
Q1 2026Apr 30, 2026$8.55$6.97+22.7%
Q4 2025Feb 4, 2026$7.54$6.91+9.1%
Q3 2025Oct 30, 2025$7.02$5.69+23.4%
Next earningsThu, Oct 29·consensus EPS $9.92

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$19.8B+55.5%81.9%44.7%$8.27$3.0B
Q4 FY25$19.3B+42.6%85.1%45.5%$7.41$677.9M
Q3 FY25$17.6B+53.9%82.9%47.6%$6.22$8.6B
Q2 FY25$15.6B+37.6%84.3%45.8%$6.30$1.3B

Forward consensus

5-year forecast · up to 25 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$88.5B$87.0B – $91.6B$36.57$32.95 – $39.1420
FY27$102.2B$98.1B – $106.3B$46.92$41.06 – $51.8320
FY28$114.1B$102.3B – $128.9B$53.87$47.53 – $59.5525
FY29$123.4B$115.0B – $131.7B$60.97$55.60 – $66.3012
FY30$132.9B$123.9B – $141.9B$66.89$61.00 – $72.7312

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.81%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+10.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 848.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 17Patrik JonssonPresident6.5K sh$7.6MSellAug 10Donald A ZakrowskiSVP, Finance, & CAO2.0K sh$2.4MSellAug 7Anat HakimEVP, GC & Secretary5.0K sh$6.0MSellJun 10Ilya YuffaEVP&Pres, LLY USA&Global Capab2.5K sh$2.9MSellMay 6Lilly Endowment IncFormer 10% Shareholder15.8K sh$15.8M
+ 29 other (24 awards · 3 gifts · 1 exempt · 1 inkind) in window

See when $LLY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3/ANew insider — initial holdingsSep 43/A
AI summary

Adrienne S. Brown, EVP and President of LLY Immunology at Eli Lilly & Company, filed an amended Form 3/A on September 4, 2026 to correct her initial beneficial ownership statement originally filed November 14, 2025. The amendment restates her direct ownership to 7,045.237 shares of LLY common stock, correcting an undercount from shares unintentionally omitted in the original filing and subsequent Forms 4. She also holds RSUs representing rights to receive approximately 3,669 additional LLY shares vesting in tranches through February 2028. This is an administrative correction with no economic change — no new shares were acquired or sold — and has no material impact on Lilly's capital structure.

SC 13DActivist position (5%+)Jul 30SC 13D
AI summary

Eli Lilly and Company (LLY) filed a Schedule 13D for Scribe Therapeutics, Inc. (SCTX) disclosing beneficial ownership of 1,388,161 shares equal to approximately 7.3% of post-IPO outstanding shares (calculated based on 18,864,386 shares outstanding after IPO including overallotment). The stake was acquired using Lilly's working capital following SCTX's IPO on or around July 27, 2026. Lilly's 7.3% strategic position in SCTX — a CRISPR gene editing company co-founded by Jennifer Doudna — signals a strategic interest in Scribe's base-editing technology platform, potentially a precursor to a licensing or acquisition.

3New insider — initial holdingsJul 233
AI summary

ELI LILLY & Co filed a Form 3 (initial statement of beneficial ownership) for Scribe Therapeutics, Inc. (SCTX), with 1,054,828 shares beneficially owned. Filer's relationship to issuer: Director, President, 10%+ Owner. This represents a significant beneficial ownership position. Form 3 must be filed within 10 days of becoming a new 10%+ owner or executive/director. This is an administrative ownership disclosure — no open-market transaction has occurred.

8-KShareholder voteMay 78-K — Item 5.07: Shareholder vote
AI summary

LLY held its annual meeting of stockholders around 2026-05-07 (8-K Item 5.07). Stockholders elected 2 directors to the board. Routine governance event — monitor for unusually high withhold votes as an activist signal.

+ 14 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Losszacks.com·1d agoEli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy?zacks.com·1d agoHe Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket247wallst.com·2d agoEli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Knowzacks.com·2d agoLilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsprnewswire.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NVO$PFE$MRK$JNJ$ABBV$AMGN$BMY$GILD
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport